. Myoblasts (Mb), myotubes (Mt) and one skin fibroblast sample were CpG-hypermethylated and lacked a DHS peak at the MARVELD2 TSS. Tracks from the UCSC genome browser and samples are described in the main text. Among DNA from cultured cells, only the sample from the skin fibroblast culture derived from a 10-year-old (Skin fib 1, purple box) was as highly methylated in this region as Mb and Mt. For Panel c, the four other LCLs not displayed in this panel but shown in Panel e also had a DHS peak in this region and several of them had much higher peaks than did LCL1. Figure S2 . Lack of repression-or activation-associated histone modifications in Mb and Mt at the MARVELD2 TSS. The RNA-seq track for non-strand-specific RNA-seq and histone modification tracks (ENCODE/Broad Institute, Bradley Bernstein) are shown for the indicated samples in the same region as in Figure S1 . Figure S3 . An active promoter region for TBX15 was hypermethylated in its 5' vicinity. Tracks from the UCSC genome browser are shown as described in the main article. Note that the LCL RNA in the TBX15 gene region came only from the 3' end of the gene. For reference, yellow highlighting indicates the entire transcribed region in the various tracks. The boxes in (g) show hypermethylation that correlates with transcription. Although some hypermethylation was seen in this region for HMEC, these cells did not transcribe this gene. This demonstrates, as expected, that this subregion's hypermethylation does not suffice for transcription. Figure S4 . DNA methylation around the 5' end of TBX15 is located at the borders of the wide osteoblast active-promoter region and at small promoter-like regions further upstream. Histone modification tracks are shown as in Figure S2 except that, in addition, CTCF binding and EZH2 binding from ChIP-seq (ENCODE/Broad Institute, Bradley Bernstein) are displayed. The yellow highlighted region was shown in Figure 3 of the main article. Light blue-highlighting indicates myogenic DNA hypermethylation that overlaps two ncRNA genes or H3K4methylation signal seen in osteoblasts, lung fibroblasts, mammary epithelial cells, or embryonic stem cells. No EZH2 data are available for osteoblasts. The region shown is the same as for Figure 4 . Figure S5 . Myogenic hypomethylation, active enhancer chromatin, DNaseI hypersensitivity, and inferred MyoD binding in intron 10 of TEAD4. Tracks from the UCSC genome browser are shown as described in the main article. Figure S6 . Myogenic hypomethylation, active enhancer chromatin, and inferred MyoD binding in a subregion of intron 3 of TEAD4. Tracks from the UCSC genome browser are shown as described in the main article except that here we include the RRBS tracks for facioscapulohumeral muscular dystrophy (FSH) Mb and Mt and inclusion body myositis (IBM) Mb. Mb3, Mt3, Mb7, and Mt 7 come from control individuals. For skeletal muscle, there was not enough of a difference between its low methylation level and the examined non-muscle samples for it to be significantly hypomethylated. Figure S7 . Myogenic hypomethylation around exon 7 of TEAD4 in a region with histone modifications indicative of active transcription. Tracks from the UCSC genome browser are shown as described in Figure S6 . In this figure, the three RefSeq isoforms are shown because of differences in exons in this region. Figure S8 . Expression of LSP1 specifically in myogenic cells or lymphoblastoid cells was correlated with specific DNA hypomethylation. Tracks from the UCSC genome browser are described in the main text. The purple boxes denote lymphoid epigenetic features and the orange box shows the region of skeletal muscle hypomethylation.
